Engineering firm Metronic forecasts RM180 million profit from distributing Taiwan vaccine


Medigen Vaccine Biologics Corporation has won a 470 million yuan (100 yuan=RM62.27) clinical subsidy contract from the Taiwan Centres for Disease Control (CDC), and is the first company to receive Taiwan government subsidies among four domestic companies approved by the CDC to conduct human clinical trials. – November 20, 2020.

ENGINEERING company Metronic Global Bhd expects to secure a profit of RM180 million following a memorandum of agreement (MOA) inked between its subsidiary Metronic Medicare Sdn Bhd and Taiwan-based Medigen Vaccine Biologics Corporation (MVC).

Metronic chief executive officer cum executive director, Hoo Wai Keong said the MOA established the basis for negotiation between the parties prior to a distribution agreement in which Metronic Medicare would be the distributor of MVC-made Covid-19 vaccine in Malaysia and potentially other countries.


Effective July 2018, access to full reports will only be available with a subscription. Sign-up now and enjoy one (1) week free access!

Subscribe Now!


Sign up or sign in here to comment.


Comments